Articles tagged with Fibrosis
Researchers identified common cellular mechanisms and dysfunctional processes driving post-COVID lung disease, similar to idiopathic pulmonary fibrosis. The study found shared gene expression patterns and endoplasmic reticulum stress as early triggers of both conditions.
Researchers found that men who lose their Y chromosome as they age are more likely to experience deadly heart scarring and earlier death. The study suggests an existing drug may help counteract the effects of this loss, potentially leading to longer, healthier lives for affected men.
Researchers found multiple gene variants contributing to pediatric NAFLD risk and disease severity, including novel SNPs associated with liver fibrosis. These genetic associations may guide future therapeutics for pediatric NAFLD, a chronic childhood disease linked to increased cardiovascular risk and mortality.
Researchers found that using advanced image-guided technology didn't lead to better outcomes for patients, but rather put them at higher risk of strokes. The study suggests that a simpler approach may be more effective in treating atrial fibrillation.
A recent review article highlights the crucial role of macrophages in the progression from acute kidney injury (AKI) to chronic kidney disease (CKD). The study suggests that targeting specific signaling pathways and altering macrophage activation can prevent renal fibrosis and CKD. Therapeutic strategies such as clodronate liposomes an...
Researchers at Cedars-Sinai have discovered that zinc, a common mineral, plays an important role in reversing lung damage and improving survival for patients with idiopathic pulmonary fibrosis (IPF). By identifying a molecular pathway involving zinc, the team hopes to develop new therapies to reverse IPF-related lung damage.
A new review analyzes the efficacy of current non-invasive methods for assessing non-alcoholic fatty liver disease (NAFLD) and associated conditions. Blood-based biomarker tests and imaging methods are explored, with some showing promise in early diagnosis and staging liver disorders.
Adding diffusion-weighted MRI to conventional MRI enhances the differentiation of locally recurrent tumor and post-surgical fibrosis in pancreatic ductal adenocarcinoma resection. The study found higher sensitivity with DWI, facilitating earlier detection of recurrences.
A new computer-aided diagnostic tool, Deep-Lung Parenchyma-Enhancing (DLPE), uses artificial intelligence to reveal signs of pulmonary fibrosis in COVID long-haulers, helping to explain respiratory symptoms and improve disease management.
Research finds that excessive mitochondrial damage caused by alcohol exposure can lead to chronic liver disease. Mitochondrial depolarization triggers mitophagy, a process removing damaged mitochondria; however, constant removal causes additional liver tissue damage.
A new review highlights the risks of fatty liver disease caused by metabolic dysfunction, characterized by fat accumulation in liver cells and oxidative stress. The progression of the disease can lead to inflammation, fibrosis, and cirrhosis with a high risk of hepatocellular carcinoma.
Researchers have found that flu viruses can directly infect heart cells, leading to electrical malfunctions and scarring. The study suggests that clearing the viral infection may be key to reducing flu's effects on the heart.
Researchers found that hypoxia can activate immune cells called ILC2s, which respond to harmless environmental allergens and drive mucus production and inflammation in the lungs. The study identifies adrenomedullin as a new target for treating inflammatory and allergic lung diseases.
A study published in JCI Insight reveals that epigenetic drugs targeting BRD4 significantly reduce scarring in patients with scleroderma. The findings could lead to repurposing these drugs for faster relief from debilitating symptoms of this chronic disease.
Researchers at the Medical University of South Carolina have developed a highly accurate and minimally invasive test for detecting liver fibrosis. The test, GlycoFibroTyper, measures changes in sugar molecules attached to antibodies in patient blood samples.
Researchers at Brigham and Women's Hospital discovered two mediators of fibrosis, KLF10 and IL-9, which could be potential therapeutic targets. Injection of mice with IL-9 neutralizing antibodies reversed fibrosis and prevented organ dysfunction.
A new study has identified a strong predictor for the development of clinically important liver problems in people with Hemochromatosis. Researchers found that 84% of those with advanced liver fibrosis also had arthritis, highlighting the importance of early detection and monitoring.
A new study has found a clear link between silica exposure and severe black lung disease in contemporary coal miners. The researchers attributed the resurgence of progressive massive fibrosis to changes in mining technology, such as mechanized coal extraction devices introduced in the 1950s.
Scientists create nanoparticles coated in mannose to block production of scar-promoting protein in lung cells. The treatment holds promise for preventing severe lung scarring disease.
Researchers at Osaka City University found that globin family members can suppress liver inflammation and fibrosis in mice. The proteins' antioxidant capacity was greater than glutathione and vitamin C, suggesting a potential therapy for liver fibrosis.
Scientists at University of Illinois and Mie University develop monoclonal antibodies to prevent lung cell death in mouse models of idiopathic pulmonary fibrosis and acute respiratory disease syndrome. Non-invasive diagnostic tools also presented could aid in predicting disease progression and identifying patients at risk.
The American College of Chest Physicians journal features cutting-edge original research on various chest medicine topics, including asthma, COPD, critical care, and sleep. The March issue includes a special series on nontuberculous mycobacterial pulmonary disease, offering insights into clinical epidemiology, risk factors, and diagnosis.
A biodegradable nanoparticle has shown promise in reducing skin and lung scarring in mice with scleroderma. The treatment targets specific immune cells responsible for the disease's chronic inflammation and scarring.
Researchers found a relationship between regionalized fibrosis in the left ventricle and mitral valve prolapse disease, suggesting potential benefits from earlier surgical intervention. Advanced fibrosis could be added to traditional markers for mitral valve repair.
A new study suggests that incomplete lung cell repair may contribute to the development of chronic fibrotic lung disease in COVID-19 and non-COVID patients. The research proposes novel therapies to promote healthy regeneration and prevent scarring.
A new pathway has been discovered to explain how excessive alcohol consumption damages the liver, specifically through mitochondrial dysfunction. By targeting an enzyme called MATα1, researchers believe they can develop a new treatment for people suffering from alcohol-associated liver disease.
Researchers found that higher monocyte counts are linked to early signs of injury and scarring on lung imaging among community-dwelling adults. This suggests that hyperactive monocytes may contribute to lung injury at the early stages of interstitial lung disease.
Researchers at Brown University have developed a new laboratory test model to investigate fibrosis treatments without the use of animals. The model uses human cells and replicates not only the structure of human tissue but also its mechanics, enabling scientists to study the underlying mechanisms of fibrosis and test potential treatments.
Researchers at MUSC identified a potent antifibrotic peptide that reverses scarring in human and mouse tissues by activating an antifibrotic pathway. The E4 peptide has the potential to treat various diseases, including heart disease, lung fibrosis, liver cirrhosis, and chronic kidney disease.
Research from MUSC suggests that physicians should be cautious when using laboratory tests to diagnose alcoholic cirrhosis due to false negative results. Patients with advanced liver disease often show subtle signs and symptoms in the early stages of cirrhosis.
Researchers found that macrophages play a central role in COVID-19-related respiratory failure, leading to fibroproliferative ARDS and prolonged ventilation. Extensive tissue damage and scar tissue formation are characteristic of severe lung failure.
Pathologists have discovered that some patients with lingering COVID-19 symptoms may have underlying chronic lung disease prior to their infection. This finding suggests that clinicians should carefully consider alternative explanations for respiratory symptoms beyond long COVID.
Researchers found that candesartan reduces accumulation of extracellular matrix proteins and normalizes blood flow in mice with hereditary cerebral small vessel disease. The study suggests a potential new treatment avenue for age-related cerebral arteriopathy.
Researchers have developed a 3D cell culturing platform that allows study of lung fibroblasts and their microenvironment, enabling measurement of cell behaviors and microenvironment changes involved in IPF disease progression. The system's versatility enables personalized medicine and potential applications in studying other diseases.
Researchers at Tokyo Medical and Dental University discovered a genetic variant associated with a poorer prognosis of chronic hypersensitivity pneumonitis. The variant, rs5743899, was linked to increased immune activation and fibrosis, leading to reduced lung function in patients.
Researchers aim to reverse tissue damage and scar buildup in lungs affected by Idiopathic Pulmonary Fibrosis (IPF) using a protein domain. The team hopes to identify therapeutic agents that can be used to treat the disease, which affects 100,000 Americans annually.
Scientists discovered an important protective response in the heart that can prevent excessive scarring after a heart attack. The study found that this reactive response can limit cardiac fibrosis by preventing oxidant build-up in heart cells, potentially leading to new therapies to repair scarring damage.
Researchers have identified a novel estrogen compound that provides benefits similar to hormone replacement therapy but without the risk factors associated with it. The compound has been shown to reduce excess lipid deposition in the liver and prevent the progression of fibrosis, which can lead to liver failure and metabolic problems.
Researchers found that hepatitis C treatment reduces the activity of proteins involved in cirrhosis, potentially indicating an early sign of liver recovery. The study suggests a possible pathway toward healing scarred liver tissue after virus elimination.
Researchers identified specific mesenchymal stromal cells within the bronchovascular bundle of lungs that play a crucial role in creating scarring through interaction with epithelial cells. These cells are thought to be triggered by immune cell attacks, leading to fibrotic scarring and rejection.
Researchers at USask discovered excessive sodium absorption in small airways of CF patients, providing new insights into the disease. The study's findings have the potential to improve life for people with CF who cannot benefit from existing medications.
A study led by Vanderbilt University Medical Center aims to identify the origins of pulmonary fibrosis in an at-risk patient population. The research, funded by Three Lakes Foundation, focuses on single-cell tissue samples from pre-symptomatic individuals to investigate the beginning of early interstitial lung disease.
A prospective study found that liver stiffness measurements obtained by shear-wave elastography decreased significantly after image-guided intervention for chronic Budd-Chiari syndrome in children. Disease recurrence was typically associated with an increase in liver stiffness measurements compared to prior assessments.
A new study found that every extra 1cm in waist circumference increases the odds of advanced fibrosis by 5% in people with type 2 diabetes. Advanced fibrosis is a late stage of non-alcoholic fatty liver disease (NAFLD), which can lead to serious liver damage.
A serum biomarker, polyubiquitinated phosphatase and tensin homolog (PTEN), was associated with a four-fold higher risk of kidney function decline. This modified form of PTEN was linked to severity of lesions in kidney structure, indicating early manifestations of diabetic kidney disease.
Researchers reverse lung fibrosis in a mouse model using Bcl-2 inhibitor ABT-199, suggesting a novel therapeutic target to treat idiopathic pulmonary fibrosis. The study finds that monocyte-derived macrophages play a key role in fibrosis progression and that targeting the Cpt1a-Bcl-2 interaction modulates apoptosis resistance.
Researchers at Skoltech have discovered structures called apical bulkheads in liver cells that are responsible for the narrow shape of bile canaliculi. The discovery reveals a key role for the Rab35 protein in regulating hepatocyte lumina formation and suggests potential avenues for medical applications in fatty liver disease and fibrosis
A subset of fibroblasts in lungs of people with idiopathic pulmonary fibrosis (IPF) produce a protein called meflin, which protects against cell aging and fibrosis. Further research could lead to novel therapies for lung fibrosis.
Non-alcoholic fatty liver disease affects 25% of the global population, leading to inflammation and fibrosis. Researchers discovered that hepatocyte reprogramming is controlled by molecular switches, resulting in dysfunction.
Researchers at University of California San Diego have found that immunotoxins targeting mesothelin can prevent liver cells from producing collagen, a precursor to fibrosis and cirrhosis. In mouse models, these antibodies killed 60-100% of human mesothelin-producing cells, reducing collagen deposition.
Researchers at Gladstone Institutes have discovered a master switch for fibrosis in the heart, which they believe could be used to treat and prevent heart failure. The study suggests that blocking this gene, MEOX1, could prevent fibrosis in other organs as well.
Researchers developed a new PET/CT radiotracer that targets activated fibroblasts in lungs, enabling direct imaging of pulmonary fibrosis. The study showed promising results, suggesting the radiotracer's potential to reduce lung biopsies and improve disease management.
Researchers at the University of Illinois Chicago have developed a microgel coating that can optimize cell-based therapy for pulmonary fibrosis. The coating boosts the therapeutic potential of donor cells by degrading scar tissue and promoting healthy lung tissue regeneration.
Fibroblasts, the cells responsible for extracellular matrices, become diseased in fibrosis. Researchers create 3D hydrogels that mimic living tissue to study fibrosis progression and epigenetic responses.
A nationwide clinical trial found no benefit from antibiotics in preventing hospitalization or death for patients with idiopathic pulmonary fibrosis. The study collected biological samples that will advance the understanding and treatment of the disease.
Researchers at UCSF have found a way to stimulate the natural surveillance system of immune cells to eliminate senescent cells, which contribute to aging and chronic diseases. This discovery offers an alternative to existing senolytic therapies and may lead to new treatments for age-related chronic diseases.
Researchers from Skoltech, Italy, discovered a new axis for preventing liver fibrosis by targeting the GILZ protein. The study used mice models and verified findings with human clinical data, suggesting that controlling the signaling pathway involving GILZ could lead to treating inflammatory liver diseases.
Researchers at UC Irvine discover the interaction between stromal progenitors and ILC2s that promotes muscle eosinophilia and fibrosis-associated gene expression. This finding could lead to the development of new treatments for Duchenne muscular dystrophy, a fatal muscle disease.
Researchers highlight the importance of myocardial fibrosis in HCM diagnosis and treatment, citing gene mutation and abnormal energy metabolism as contributing factors. The use of magnetic resonance imaging is also discussed as a diagnostic tool for fibrosis.
Researchers found a link between citrullinated vimentin, produced by lung macrophages in response to environmental pollutants, and the development of lung fibrosis. The study suggests that targeting PAD2 enzyme could attenuate cadmium/carbon black-induced fibrosis.